Price$171.04+8.09 (+4.97%)
01:30 PM07:45 PM
News · 26 weeks91+380%
2025-12-072026-05-31
Mix4790d
- Insider26(55%)
- Other12(26%)
- SEC Filings5(11%)
- Earnings2(4%)
- Analyst2(4%)
Latest news
25 items- INSIDERDirector Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERChief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERVP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- PRIntegrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster InsightsIntegrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysis DRAGEN™ pipelines optimized for IDT custom hybrid capture panels enable accurate, efficient, variant detection The DRAGEN Somatic for IDT Custom Panels feature a new, low-quality FFPE mode to analyze challenging samples Integrated DNA Technologies (IDT), a Danaher company and global leader in genomics, today announced a strategic collaboration with Illumina, Inc. (NASDAQ:ILMN) to enable a DRAGEN™ secondary analysis pipeline for IDT xGen™ FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an
- INSIDERAmendment: SEC Form 4 filed by Director Meister Keith A.4/A - ILLUMINA, INC. (0001110803) (Issuer)
- PRIllumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology researchAutomating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panelsSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to acc
- PRIllumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD researchAn advanced research workflow for fast, flexible detection of molecular residual disease during and following treatmentSolution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD marketSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer
- SECIllumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
- INSIDERDirector King David P was granted 2,072 shares (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Siegel Susan E was granted 2,072 shares, increasing direct ownership by 14% to 16,535 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Ullem Scott B. was granted 2,072 shares, increasing direct ownership by 24% to 10,863 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Schiller Philip W was granted 2,072 shares, increasing direct ownership by 10% to 22,220 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Richo Anna was granted 2,072 shares, increasing direct ownership by 32% to 8,527 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Meister Keith A. was granted 2,072 shares, increasing direct ownership by 45% to 6,638 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Gottlieb Scott was granted 2,072 shares, increasing direct ownership by 16% to 14,795 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Dorsa Caroline covered exercise/tax liability with 1,512 shares and was granted 2,072 shares, increasing direct ownership by 4% to 15,754 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERSEC Form 3 filed by new insider King David P3 - ILLUMINA, INC. (0001110803) (Issuer)
- PRDavid P. King elected to Illumina's Board of DirectorsFormer Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's BoardSAN DIEGO, May 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care. "We are delighted to welcome David to the Illumina Board," said Jacob Thaysen, chief executive officer of Illumina. "David brings deep regulatory knowledge, broad industry credibility, and t
- PRIllumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impactSAN DIEGO, May 19, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expanding equitable access to genomics while delivering measurable impact for patients, communities, and health systems worldwide. It reinforces Illumina's mission-driven culture, sustainability goals, and commitment to genomics for good. "More than 20 million people are diagnosed with cancer each year. Rare disease patients face years-long diagnostic odysseys to find answers. Health systems are under growing pressure to deliver better outcomes with fewer resources. Genomics can help meet these challenge
- SECSEC Form SD filed by Illumina Inc.SD - ILLUMINA, INC. (0001110803) (Filer)
- ANALYSTRBC Capital Mkts resumed coverage on Illumina with a new price targetRBC Capital Mkts resumed coverage of Illumina with a rating of Outperform and set a new price target of $170.00
- INSIDERDirector Meister Keith A. sold $47,931,975 worth of shares (329,460 units at $145.49) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- ANALYSTIllumina upgraded by Daiwa Securities with a new price targetDaiwa Securities upgraded Illumina from Neutral to Outperform and set a new price target of $155.00
- INSIDERSEC Form 4 filed by Director Meister Keith A.4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERSVP, Strategy/Corp Development Wedel Christensen Jakob covered exercise/tax liability with 233 shares and sold $97,328 worth of shares (700 units at $139.04), decreasing direct ownership by 6% to 15,056 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
ILMN FAQ
7 questionsWhat does Illumina Inc. do?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic...Where does ILMN stock trade?
Illumina Inc. (ILMN) is listed on NASDAQ.What sector and industry is ILMN in?
Illumina Inc. operates in the Health Care sector, Medical Specialities industry.When did Illumina Inc. go public?
Illumina Inc. (ILMN) completed its IPO in 2000.What are analysts saying about ILMN?
Illumina Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Outperform on 2026-05-15.What companies are similar to ILMN?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), QGEN (Qiagen N.V.), TXG (10x Genomics Inc.). Compare ILMN side-by-side with any of them on Quantisnow.How can I track ILMN on Quantisnow?
Quantisnow aggregates Illumina Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ILMN to receive live email and push alerts on every new disclosure.